[Neurofibromatosis type 2 in the otorhinolaryngological practice].

Q3 Medicine
M V Subbotina, A V Berseneva
{"title":"[Neurofibromatosis type 2 in the otorhinolaryngological practice].","authors":"M V Subbotina, A V Berseneva","doi":"10.17116/otorino20248901137","DOIUrl":null,"url":null,"abstract":"<p><p>Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disease (frequency 1 in 25-90 000) characterized by the formation of tumors of the central nervous system due to a mutation in the <i>NF2</i> gene on chromosome 22q12. Bilateral vestibular schwannomas are recognized as absolute diagnostic criteria of NF2 and occur in 95% of patients, are accompanied by hearing impairment, manifest at the age of 18-24 years. Skin manifestations can precede vestibular schwannomas for several years and predict the course of the disease: neurofibromas, cafe-au-lait macules, hypopigmented spots, recently described mesh capillary malformations. Despite the benign nature of schwannomas, they can lead to hearing loss, vestibular dysfunction, facial nerve paralysis, gait disorders, pain and convulsions, there is a risk of early death from compression of the brain stem. The probability of progressive hearing loss is partly determined by the type of mutation. We described a clinical case of NF2 in a 21-year-old patient with bilateral vestibular schwannomas without hearing loss, whose skin examination by ENT specialist revealed this disease. The importance of the presented observation is that the doctor should assume neurofibromatosis type 2 in a young patient with bilateral vestibular schwannomas. It is necessary to undertake a further examination of this patient, including: skin examination for the identification of characteristic neurofibromas and cafe-au-lait macules, consultation with an ophthalmologist, neurologist, MRI of the brain and spinal cord with contrast, genetic analysis - for timely initiation of therapy that prevents hearing loss and vestibular disorders.</p>","PeriodicalId":23575,"journal":{"name":"Vestnik otorinolaringologii","volume":"89 1","pages":"37-41"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik otorinolaringologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/otorino20248901137","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disease (frequency 1 in 25-90 000) characterized by the formation of tumors of the central nervous system due to a mutation in the NF2 gene on chromosome 22q12. Bilateral vestibular schwannomas are recognized as absolute diagnostic criteria of NF2 and occur in 95% of patients, are accompanied by hearing impairment, manifest at the age of 18-24 years. Skin manifestations can precede vestibular schwannomas for several years and predict the course of the disease: neurofibromas, cafe-au-lait macules, hypopigmented spots, recently described mesh capillary malformations. Despite the benign nature of schwannomas, they can lead to hearing loss, vestibular dysfunction, facial nerve paralysis, gait disorders, pain and convulsions, there is a risk of early death from compression of the brain stem. The probability of progressive hearing loss is partly determined by the type of mutation. We described a clinical case of NF2 in a 21-year-old patient with bilateral vestibular schwannomas without hearing loss, whose skin examination by ENT specialist revealed this disease. The importance of the presented observation is that the doctor should assume neurofibromatosis type 2 in a young patient with bilateral vestibular schwannomas. It is necessary to undertake a further examination of this patient, including: skin examination for the identification of characteristic neurofibromas and cafe-au-lait macules, consultation with an ophthalmologist, neurologist, MRI of the brain and spinal cord with contrast, genetic analysis - for timely initiation of therapy that prevents hearing loss and vestibular disorders.

[耳鼻喉科实践中的神经纤维瘤病 2 型]。
神经纤维瘤病 2 型(NF2)是一种罕见的常染色体显性遗传病(发病率为 1/25-90,000),其特征是由于染色体 22q12 上的 NF2 基因发生突变而形成中枢神经系统肿瘤。双侧前庭分裂瘤被认为是 NF2 的绝对诊断标准,95% 的患者会出现这种情况,并伴有听力障碍,发病年龄为 18-24 岁。皮肤表现可先于前庭分裂瘤数年出现,并可预测病程:神经纤维瘤、咖啡色斑、色素减退斑,以及最近描述的网状毛细血管畸形。尽管裂头瘤是良性的,但它会导致听力损失、前庭功能障碍、面神经麻痹、步态障碍、疼痛和抽搐,还有可能因压迫脑干而早期死亡。渐进性听力损失的概率部分取决于突变类型。我们描述了一个 NF2 临床病例,患者 21 岁,患有双侧前庭分裂瘤,但没有听力损失,耳鼻喉科专家对其进行皮肤检查时发现了这种疾病。本病例的重要意义在于,对于患有双侧前庭分裂瘤的年轻患者,医生应假设其患有神经纤维瘤病 2 型。有必要对该患者进行进一步检查,包括:皮肤检查,以确定特征性神经纤维瘤和咖啡色斑疹;咨询眼科医生和神经科医生;脑部和脊髓核磁共振成像造影;基因分析--以便及时开始治疗,预防听力损失和前庭功能紊乱。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Vestnik otorinolaringologii
Vestnik otorinolaringologii Medicine-Otorhinolaryngology
CiteScore
0.80
自引率
0.00%
发文量
69
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信